rituximab + paclitaxel + ruxolitinib

This is a combination regimen consisting of three agents: - **Rituximab** is a monoclonal antibody targeting CD20, primarily used in the treatment of B-cell malignancies and certain autoimmune diseases. It works by binding to the CD20 antigen on B lymphocytes, leading to cell lysis through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. - **Paclitaxel** is a small molecule chemotherapeutic agent that stabilizes microtubules, inhibiting their disassembly during cell division and thereby inducing apoptosis in rapidly dividing cells. - **Ruxolitinib** is an orally bioavailable small molecule inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2), which are key mediators in cytokine signaling pathways involved in hematopoiesis and immune function. While combinations such as ruxolitinib plus paclitaxel[1] or rituximab plus other JAK inhibitors have been studied for various cancers, there are no published clinical trials or regulatory approvals specifically for the triple combination of rituximab + paclitaxel + ruxolitinib as a single regimen. Each component has established use individually or in dual combinations for hematologic malignancies (e.g., non-Hodgkin lymphoma, myelofibrosis) or solid tumors (e.g., breast cancer)[3][6][7]. The rationale for combining these agents would be to target both malignant B cells directly (rituximab), disrupt mitosis in proliferating tumor cells (paclitaxel), and inhibit pro-survival cytokine signaling pathways implicated in cancer progression (ruxolitinib).